Valuation dashboard for Natera, Inc. (NTRA) with P/E N/A, P/B 35.17, EV/EBITDA -346.90 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations.
Analysis Summary
Natera, Inc. reported revenue of $2.31B in the most recent fiscal year, growing at a 5-year CAGR of 42.6%.
Trailing-twelve-month margins: gross margin 65.3%, operating margin -10.7%, net margin -7.1%.
At $414.30 (closing price, October 30, 2026), NTRA has negative trailing earnings (P/E not meaningful) and an ROE of -11.73%. Market capitalisation stands at $59.7B, placing it among large-cap names.
Balance sheet quality for NTRA: current ratio of 3.4. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 35.17 |
| EV / EBITDA | -346.90 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-321.52 |
| vs Current Price | -177.6% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| NTRA | Natera, Inc. | $59.7B | 35.17 | -11.7% | |
| BLLN | BillionToOne, Inc. | $5.3B | 182.74 | 9.86 | 7.9% |
| VCYT | Veracyte, Inc. | $4.0B | 35.72 | 2.98 | 8.6% |
| TMO | Thermo Fisher Scientific Inc. | $257.7B | 36.76 | 4.71 | 13.3% |
| 0R0H.L | Thermo Fisher Scientific Inc. | $248.1B | 35.48 | 4.55 | 13.3% |
| DHR | Danaher Corporation | $163.3B | 38.01 | 3.05 | 8.2% |
| 0R2B.L | Danaher Corporation | $157.7B | 37.66 | 3.03 | 8.2% |
| 0HAV.L | Agilent Technologies, Inc. | $50.1B | 34.00 | 6.63 | 20.5% |
Price
| Price | $414.30 (closing price, October 30, 2026) |
| Market Cap | $59.7B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -11.73% |
| Return on Invested Capital | -10.02% |
| Return on Assets | -7.24% |
| Gross Margin | 65.30% |
| Operating Margin | -10.70% |
| Net Margin | -7.11% |
Related companies: BLLN · VCYT · TMO · 0R0H.L · DHR · 0R2B.L · 0HAV.L · A
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of NTRA: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks